ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma

This study has been completed.

Sponsors and Collaborators: National Institute on Aging (NIA)
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00003993
  Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining chemotherapy and interleukin-2 may kill more cancer cells.

PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-2 when given together with bryostatin 1 in treating patients with refractory solid tumors or lymphoma.


Condition Intervention Phase
Lymphoma
Small Intestine Cancer
Unspecified Adult Solid Tumor, Protocol Specific
Drug: aldesleukin
Drug: bryostatin 1
Phase I

MedlinePlus related topics:   Cancer    Intestinal Cancer    Lymphoma   

Drug Information available for:   Aldesleukin    Interleukin-2    Bryostatin 1   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment
Official Title:   A Phase lb Trial of the Combination of Bryostatin-1 and Low Dose Interleukin-2: Evaluation of the Functional and Molecular Status of Human Monocytes as Antigen Presenting Cells

Further study details as provided by National Cancer Institute (NCI):

Estimated Enrollment:   24
Study Start Date:   September 1999
Primary Completion Date:   July 2008 (Final data collection date for primary outcome measure)

Detailed Description:

OBJECTIVES:

  • Determine the safety and side effects of bryostatin 1 and interleukin-2 in patients with refractory solid tumors or lymphomas.
  • Determine the maximum tolerated dose for interleukin-2 with bryostatin 1 in these patients.
  • Determine whether bryostatin 1 and interleukin-2 increase the expression of recognition and costimulatory molecules on human monocytes and their ability to act as antigen presenting cells.
  • Assess any anti-tumor response in these patients treated with this regimen.

OUTLINE: This is a dose escalation study of interleukin-2.

Patients receive bryostatin 1 IV over 24 hours on days 1 and 8, and interleukin-2 subcutaneously on days 1-5 and days 8-12. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of interleukin-2 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.

PROJECTED ACCRUAL: A total of 18-24 patients will be accrued for this study in less than 2 years.

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

DISEASE CHARACTERISTICS:

  • Histologically proven solid tumor or lymphoma that is not curable by surgery, radiotherapy, or standard chemotherapy, or for which no curative therapy exists
  • Prostate cancer patients must have the following:

    • Tumor progression following blockade of both testicular and adrenal androgens
    • Serum testosterone in the castrate range (less than 20 ng/mL)
    • At least 3 months since prior suramin therapy
    • At least 4 weeks since prior flutamide or other antiandrogen medication and no evidence of response to treatment
    • Luprolide should continue if no prior orchiectomy
  • No prior or concurrent brain metastases

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • ECOG 0 or 1

Life expectancy:

  • At least 3 months

Hematopoietic:

  • WBC at least 3,500/mm^3 OR
  • Granulocyte count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • Hemoglobin at least 8 g/dL

Hepatic:

  • Hepatitis B surface antigen negative
  • PT no greater than 14 seconds
  • PTT no greater than 35 seconds
  • Bilirubin no greater than 1.5 mg/dL unless due to Gilbert's disease
  • SGOT and SGPT no greater than 2.5 times upper limit of normal (ULN)
  • Alkaline phosphatase no greater than 2.5 times ULN
  • Albumin at least 2.5 g/dL

Renal:

  • Creatinine no greater than 1.5 mg/dL OR
  • Creatinine clearance at least 50 mL/min
  • Corrected calcium at least 8.0 mg/dL, but no greater than 10.7 mg/dL

Cardiovascular:

  • No prior myocardial infarction, coronary artery disease (CAD), congestive heart failure, second or third degree AV block, or cardiac arrhythmias requiring treatment
  • No evidence of CAD on EKG

Pulmonary:

  • FEV1-1 at least 70% predicted
  • DLCO at least 60% predicted

Other:

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • HIV negative
  • At least 1 week since active infection requiring antibiotics
  • No other medical or psychiatric condition that would preclude study
  • No prior or concurrent seizure disorders controlled with medication

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • At least 4 weeks since prior interleukin-2
  • At least 4 weeks since other prior biologic therapy for solid tumors or lymphomas

Chemotherapy:

  • See Disease Characteristics
  • At least 4 weeks since prior bryostatin 1
  • At least 4 weeks since other prior chemotherapy for solid tumors or lymphomas

Endocrine therapy:

  • See Disease Characteristics
  • At least 4 weeks since other prior endocrine therapy for solid tumors or lymphomas
  • No absolute requirement for corticosteroids

Radiotherapy:

  • See Disease Characteristics
  • At least 4 weeks since prior radiotherapy for solid tumors or lymphomas

Surgery:

  • See Disease Characteristics
  • At least 4 weeks since prior surgery for solid tumors or lymphomas

Other:

  • No absolute requirement for nonsteroidal anti-inflammatory drugs or H2 blockers
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00003993

Locations
United States, Maryland
National Institute on Aging - Baltimore    
      Baltimore, Maryland, United States, 21224-6825

Sponsors and Collaborators

Investigators
Study Chair:     Igor Espinoza-Delgado, MD     Gerontology Research Center    
  More Information


Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site
 

Study ID Numbers:   CDR0000067198, NCI-T99-0015, LSUMC-9901
First Received:   November 1, 1999
Last Updated:   August 2, 2008
ClinicalTrials.gov Identifier:   NCT00003993
Health Authority:   United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage IV adult Hodgkin lymphoma  
recurrent adult Hodgkin lymphoma  
stage IV cutaneous T-cell non-Hodgkin lymphoma  
recurrent cutaneous T-cell non-Hodgkin lymphoma  
small intestine lymphoma  
unspecified adult solid tumor, protocol specific  
stage IV grade 1 follicular lymphoma  
stage IV grade 2 follicular lymphoma  
stage IV grade 3 follicular lymphoma  
stage IV adult diffuse small cleaved cell lymphoma  
stage IV adult diffuse mixed cell lymphoma  
stage IV adult diffuse large cell lymphoma  
stage IV adult immunoblastic large cell lymphoma  
stage IV adult lymphoblastic lymphoma  
stage IV adult Burkitt lymphoma  
recurrent grade 1 follicular lymphoma
recurrent grade 2 follicular lymphoma
recurrent grade 3 follicular lymphoma
recurrent adult diffuse small cleaved cell lymphoma
recurrent adult diffuse mixed cell lymphoma
recurrent adult diffuse large cell lymphoma
recurrent adult immunoblastic large cell lymphoma
recurrent adult lymphoblastic lymphoma
recurrent adult Burkitt lymphoma
stage IV adult T-cell leukemia/lymphoma
recurrent adult T-cell leukemia/lymphoma
primary central nervous system lymphoma
intraocular lymphoma
stage IV mantle cell lymphoma
recurrent mantle cell lymphoma

Study placed in the following topic categories:
Sezary syndrome
Lymphoma, Mantle-Cell
Hodgkin lymphoma, adult
Lymphoma, small cleaved-cell, diffuse
Lymphoma, large-cell, immunoblastic
Central nervous system lymphoma, primary
Duodenal Neoplasms
Mycoses
Lymphoma, Large-Cell, Anaplastic
Hodgkin Disease
Lymphoma, Large B-Cell, Diffuse
Immunoproliferative Disorders
Digestive System Neoplasms
Leukemia, B-cell, chronic
Bryostatin 1
Aldesleukin
B-cell lymphomas
Leukemia, T-Cell
Gastrointestinal Neoplasms
Anaplastic large cell lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, T-Cell, Cutaneous
Hodgkin's disease
Gastrointestinal Diseases
Cutaneous T-cell lymphoma
Lymphoma, Follicular
Lymphoma, B-Cell, Marginal Zone
Sezary Syndrome
Mycosis Fungoides
Lymphoma, B-Cell

Additional relevant MeSH terms:
Anti-Infective Agents
Anti-HIV Agents
Neoplasms by Histologic Type
Immunologic Factors
Immune System Diseases
Antineoplastic Agents
Physiological Effects of Drugs
Adjuvants, Immunologic
Antiviral Agents
Ileal Diseases
Pharmacologic Actions
Neoplasms
Neoplasms by Site
Anti-Retroviral Agents
Jejunal Diseases
Analgesics, Non-Narcotic
Sensory System Agents
Therapeutic Uses
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 30, 2008




Links to all studies - primarily for crawlers